Klaria Pharma (KLAR) Q2 2026 earnings summary

Executive summary

• Focus during Q2 2026 was on strengthening financial position and preparing for the launch of Sumatriptan Alginate Film in Europe.

• Bridge financing of 25 MSEK secured in June 2026 to support liquidity and strategic alternatives.

• Preparations for a rights issue of up to 148 MSEK announced after the period, with strong investor interest.

• Ongoing business development with BDO and continued patent protection efforts for key products.

Financial highlights

• Net sales for Q2 2026 were 0 TSEK (0 TSEK in Q2 2025); for H1 2026, 100 TSEK (8,985 TSEK in H1 2025).

• R&D expenses for Q2 2026 were 4,414 TSEK (7,090 TSEK); for H1 2026, 9,328 TSEK (10,515 TSEK).

• Profit after tax for Q2 2026 was -12,887 TSEK (-20,118 TSEK); for H1 2026, -21,542 TSEK (-21,710 TSEK).

• Cash flow from operating activities for Q2 2026 was -14,792 TSEK (-2,319 TSEK); for H1 2026, -14,874 TSEK (-1,718 TSEK).

• Cash and cash equivalents at June 30, 2026 were 8,468 TSEK (1,969 TSEK).

Outlook and guidance

• Launch preparations for Sumatriptan Alginate Film in Europe are progressing, with cost reimbursement milestones expected soon.

• Targeting 10-30% market share of the European Sumatriptan market, valued at approximately 1 billion SEK annually.

• Anticipates stable royalty cash flow and milestone payments upon successful market entry.

• Business development for additional licensing agreements outside Europe is ongoing.